Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 4

Patient demographics and baseline characteristics (full analysis set).

Variable	Treatment group	Control group	Statistics	value
Gender			2.68 (CHISQ test)	0.1017
Male	106 (61.99)	121 (70.35)
Female	65 (38.01)	51 (29.65)
Age (years)	51.89 ± 13.12	52.03 ± 12.62	−0.10 (grouped T-test)	0.9197
Disease duration (months)	59.92 ± 84.69	62.81 ± 77.05	−0.33 (grouped T-test)	0.7424
Systolic blood pressure (mmHg)	124.57 ± 7.24	123.84 ± 7.90	0.89 (grouped T-test)	0.3730
Diastolic blood pressure (mmHg)	76.94 ± 5.24	76.56 ± 6.12	0.61 (grouped T-test)	0.5408
24-hour proteinuria (g/24 h)	0.73 ± 0.61	0.72 ± 0.67	0.22 (grouped T-test)	0.8298
Urea nitrogen (mmol/L)	8.93 ± 3.26	8.89 ± 3.10	0.09 (grouped T-test)	0.9291
Serum creatinine (μmol/L)	150.27 ± 37.12	147.56 ± 29.46	0.75 (grouped T-test)	0.4540
eGFR (ml/min/1.73 m^2)	43.57 ± 9.29	44.37 ± 9.09	−0.81 (grouped T-test)	0.4171